Dizal’s ZEGFROVY® (sunvozertinib) Receives FDA Accelerated Approval as the Only Targeted Oral Treatment for Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
— ZEGFROVY is the onlyapprovedtargeted oral treatmentforNSCLCwith EGFRexon20ins — Approval follows the U.S. FDA's Priority Review and is supported by the pivotal WU-KONG1 Part Bstudy, in which ZEGFROVY demonstrated statistically significant and clinically meaningful benefits to patients Dizal (SSE:688192), a biopharmaceutical company committed to developing novel medicines for the treatment of cancer and immunological diseases, […]